SPECIAL REPORT

The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.

Read More

A number of recent studies have suggested that alterations in the gut microbiome (dysbiosis) may contribute to the onset and/or worsening of multiple sclerosis. Two new papers, scheduled for publication this week, report that certain bacterial strains promote neurodegeneration in the EAE mouse model (Cekanaviciute and colleagues. PNAS 2017; in press). Read More